FIRST FDA AUTHORIZED DEVICE FOR RADIATION-INDUCED OM

Lightening the burden of oral mucositis

A standardized, 10-minute daily photobiomodulation treatment designed to fit within the radiation therapy workflow

Request a consultation

Explore the clinical evidence

ADVANCING OM MANAGEMENT

First FDA-Authorized Device for Radiation-Induced Oral Mucositis

A standardized, 10-minute daily photobiomodulation treatment designed to fit within the radiation therapy workflow.

Request a consultation

CLINICAL IMPACT. PRACTICAL DELIVERY.

Why Choose Mureva?

Oral mucositis (OM) is a common and debilitating complication of cancer treatment, particularly among patients receiving radiation to the head and neck. It can cause significant pain, interfere with eating and swallowing, compromise nutrition, and disrupt treatment.

Mureva is FDA authorized to lower the severity of radiation-induced OM and associated complications in eligible adults receiving radiation, with or without chemotherapy.

REDUCE SEVERE OM

Clinical findings showed fewer patients developing severe OM, fewer days with severe OM and less pain, along with favorable findings in treatment continuity.

PROTECT PATIENT FUNCTION

Supportive findings in swallowing, taste and feeding-tube placement suggest Mureva may help patients preserve function and stay nourished throughout treatment.

SIMPLIFY PBM DELIVERY

A standardized 10-minute daily treatment designed to fit within existing radiation workflows and make PBM practical for routine care.

CLINICAL IMPACT. PRACTICAL DELIVERY.

Why Choose Mureva?

Nearly all head and neck cancer patients develop oral mucositis during radiation. Photobiomodulation (PBM) has been the guideline-recommended answer. Mureva closes the gap.

REDUCE SEVERE OM

Mureva lowers the severity, incidence, and duration of severe OM, reducing pain and helping patients stay on their radiation schedule.

PROTECT PATIENT FUNCTION

By protecting swallowing and taste and reducing feeding tube placement, Mureva helps patients stay nourished and stronger through treatment.

SIMPLIFY PBM DELIVERY

A standardized 10-minute daily treatment that fits within your existing radiation workflow and scales across routine care

DE NOVO AUTHORIZATION

First FDA-authorized device for radiation-induced oral mucositis

Severe OM through two weeks post-IMRT in the FDA-indicated population

RELATIVE REDUCTION

in severe oral mucositis

p=0.016

Percent of Patients with Severe OM

Sham81%

81%

Mureva37%

37%

Severe oral mucositis (WHO grade 3 or higher) incidence through two weeks post-IMRT; adults receiving radiation to less than 75% of the oral cavity: FDA-indicated subgroup (n=40)

Explore the evidence

10 MINUTE TREATMENT

See how Mureva works

A simple, daily treatment delivered prior to radiation, Mureva uses dual intraoral mouthpieces designed to target the tissues most susceptible to developing OM. The per-patient, one-size-fits-all mouthpieces, designed for adults, are soft, flexible, and well tolerated, making treatment comfortable from the first to the last day of radiation.

clinician testimonials

Hear From Our Clinicians

Oral mucositis remains a significant challenge during head and neck radiation. Hear from clinicians about how Mureva provides a practical, standardized approach to delivering guideline-recommended PBM within routine radiation care.

“Severe oral mucositis remains a major challenge during head and neck radiation because it can impair eating and swallowing and add substantially to the burden of treatment. This randomized, sham-controlled trial demonstrated that Mureva OM significantly reduced severe oral mucositis, including in the FDA-indicated patient population, while achieving a very high treatment completion rate. These findings support a standardized and practical approach to incorporating photobiomodulation into supportive care.”

Kenneth S. Hu, MD

Professor of Radiation Oncology and Otolaryngology-Head and Neck Surgery

“Through many studies and systematic reviews, PBM has demonstrated efficacy in preventing the incidence and severity of OM in patients receiving radiation therapy for head and neck cancers. For a company like Mureva to [produce] a really rigorously engineered device that’s really simple to use and train a center on: that’s what’s needed for the field.”

Nathaniel Simon Treister, DMD

Chief, Division of Oral Medicine and Dentistry, Associate Professor of Oral Medicine, Infection, and Immunity

“We saw a patient that was enrolled in the PBM trial who was very concerned of developing painful mouth sores from OM and did not because of the Mureva device. The patient was crying because of happiness, because he didn’t have any mouth sores or any pain. To me, that’s success.“

Alessandro Villa, DDS, PhD, MPH

Chief of Oral Medicine, Oral Oncology, and Dentistry, President ISOO

“The benefit to using Mureva PBM is significant in the reduction of oral mucositis for patients undergoing head and neck cancer therapy. They do better, they have less pain, less mucositis, and overall feel better.”